000			03326cam a2200349 a 4500
003			EG-GiCUC
005			20250223032655.0
008			210118s2020 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.28.M.Sc.2020.Mo.A
100	0		_aMostafa Bakr Ali Mohamed Ashour
245	1	0	_aAssessment of growth velocity in chronically hepatitis b virus infected children / _cMostafa Bakr Ali Mohamed Ashour ; Supervised Mona Elsaid Elraziky , Engy Adel Mogahed , Shaymaa Ahmed Elbehairy
246	1	5	_aتقييم سرعة النمو فى الأطفال المصابين بالالتهاب الكبدى الفيروسى المزمن - ب
260			_aCairo : _bMostafa Bakr Ali Mohamed Ashour , _c2020
300			_a110 P. : _bcharts , facimiles ; _c2020
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520			_aBackground: Chronic infections and liver diseases may influence the growth and development of children by leading to malnutrition. Aim of work: To assess growth and growth velocity in chronically HBV infected children following at the pediatric hepatology clinic, Cairo university children's hospital and to correlate the growth parameters to disease activity and effect of therapy. Methods: This observational study included 57 children. Their data were retrieved from files including: name, age, clinical history, anthropometric measurements, investigations and treatment received. Results: The studied cases included 35 males. Their age ranged between 3 months and 16 years at their first presentation. History of maternal HBV was present in 96.5% of the patients. Thirty-three cases were immune tolerant at time of presentation. Baseline anthropometric measures showed that 2 cases had weight and height SD below <-2, 5 cases had height SDs <-2 and 1 case had weight and BMI SD < - 2.No significant difference was observed in growth velocity of studied cases regarding treatment status (p=0.42). Seroconversion (HBeAb positivity) was achieved in 21 cases (36.8%). In cases with positive HBeAb, seven cases showed improvement in weight and 4 showed improvement in height compared to cases with HBeAb negative who showed no change (p=0.02). Levels of transaminases were significantly higher among cases with negative HBeAb (p=0.019). There was no effect on height velocity in patients receiving PEG-IFN during treatment period compared to post treatment follow up velocity (p=0.9). Conclusion: Vertical transmission is the main risk factor for HBV acquisition in Egyptian children. Chronic HBV in children did not show a negative impact on growth parameters or growth velocity. Growth velocity was not affected either by the HBV immune status or treatment type.Patients with HBV seroconversion showed a better improvement in growth parameters
530			_aIssued also as CD
653		4	_aChildren
653		4	_aGrowth velocity
653		4	_aHepatitis B Virus (HBV)
700	0		_aEngy Adel Mogahed , _eSupervisor
700	0		_aMona Elsaid Elraziky , _eSupervisor
700	0		_aShaymaa Ahmed Elbehairy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c79582 _d79582